Renal complications of cytotoxic therapy.
The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications. This article reviews the nephrotoxicity and other renal and urological complications of commonly used drugs and the clinical setting in which they are prescribed. Emphasis is placed on the mechanisms, prevention and treatment of renal damage.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D004285:Dogs; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects; D008937:Mitomycins / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects; D008926:Plicamycin / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D013311:Streptozocin / Q000009:adverse effects; D013577:Syndrome
D000970:Antineoplastic Agents; D008937:Mitomycins; D009607:Nitrosourea Compounds; D003561:Cytarabine; D011344:Procarbazine; D013311:Streptozocin; D003520:Cyclophosphamide; D001215:Asparaginase; D008926:Plicamycin; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate